David Campbell is President and Chief Executive Officer of Janux Therapeutics, Inc. (JANX). The company reported total compensation of $13,506,231 for fiscal year 2025.
| Salary | $680,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $12,459,031 |
| Non-equity incentive plan | $367,200 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $13,506,231 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Janux Therapeutics, Inc. filed April 28, 2026, accession 0001193125-26-187095.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| David Campbell this page | President and Chief Executive Officer | $13,506,231 |
| Byron Robinson | Former Chief Strategy Officer | $5,063,635 |
| Janeen Doyle | Chief Corporate and Business Development Officer | $4,669,292 |
| Zachariah McIver | Former Chief Medical Officer | $4,639,495 |
| Thomas DiRaimondo | Chief Scientific Officer | $4,345,469 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Janux Therapeutics, Inc. compensation brief.
David Campbell's compensation sits inside Janux Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.